Market structure and hospital–insurer bargaining in the Netherlands

Por Halbersma, R. S., Mikkers, M. C., Motchenkova, E., Seinen, I.
Publicado em 2010

Risk Adjustment with an Outside Option

Por Newhouse, Joseph P.
Publicado no J Health Econ (2017)

Future costs and the future of cost-effectiveness analysis

Por Garber, Alan M., Phelps, Charles E.
Publicado em 2008

The Income Gradient in Children’s Health: A Comment on Currie, Shields and Wheatley Price

Por Case, Anne, Lee, Diana, Paxson, Christina
Publicado em 2007

Introduction to the Special Issue Health Plan Payment in Regulated Competition

Por McGuire, Thomas G., van Kleef, Richard C.
Publicado no J Health Econ (2017)

Estimating Peer Effects on Health in Social Networks : A Response to Cohen-Cole and Fletcher; Trogdon, Nonnemaker, Pais

Por Fowler, J.H., Christakis, N.A.
Publicado em 2008

The Developmental Origins of Health()

Por Heckman, James J.
Publicado em 2012

Reply to commentary on costs of diabetes and its complications in Poland

Por Leśniowska, Joanna
Publicado no Eur J Health Econ (2014)

Correction to: Cost–consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma

Por Vallejo-Aparicio, Laura Amanda, Molina, Jesús, Ojanguren, Iñigo, Viejo Casas, Ana, Huerta, Alicia, Svedsater, Henrik
Publicado no Eur J Health Econ (2019)

Correction to: Cost‑effectiveness analysis of stand‑alone or combined non‑invasive imaging tests for the diagnosis of stable coronary artery disease: results from the EVINCI study...

Por Lorenzoni, Valentina, Bellelli, Stefania, Caselli, Chiara, Knuuti, Juhani, Underwood, Stephen Richard, Neglia, Danilo, Turchetti, Giuseppe
Publicado no Eur J Health Econ (2019)

What values do the public want their health care systems to use in evaluating technologies?

Por Buxton, Martin J., Chambers, James D.
Publicado em 2011

The development of new research methods for the valuation of EQ-5D-5L

Por Devlin, Nancy J., Krabbe, Paul F. M.
Publicado em 2013

Awaiting the “catharsis”

Por Yfantopoulos, John
Publicado no Eur J Health Econ (2020)

Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures?

Por Farfan-Portet, María-Isabel, Gerkens, Sophie, Lepage-Nefkens, Isabelle, Vinck, Irmgard, Hulstaert, Frank
Publicado em 2013

Choice determinants of the mobility in the Dutch health insurance market

Por Mosca, Ilaria, Schut-Welkzijn, Anoushka
Publicado em 2007

Personality and the education–health gradient: A note on “Understanding differences in health behaviors by education”

Por Conti, Gabriella, Hansman, Christopher
Publicado em 2012

Pricing vaccines and drugs in Europe: worth differentiating?

Por Garattini, Livio, Padula, Anna, Freemantle, Nicholas
Publicado no Eur J Health Econ (2020)

More room for telemedicine after COVID-19: lessons for primary care?

Por Garattini, Livio, Badinella Martini, Marco, Zanetti, Michele
Publicado no Eur J Health Econ (2020)

When are person tradeoffs valid?

Por Doctor, Jason N., Miyamoto, John, Bleichrodt, Han
Publicado em 2009

Dynamics of Work Disability and Pain

Por Kapteyn, Arie, Smith, James P., van Soest, Arthur
Publicado em 2007